Hit Counter  

Greetings 

I (no every freelance translator) am often asked to do a "trial translation" when I get in contact with a new company, or in some cases also for companies I have been working with for long years already, but where **new clients** ask for these  trials. In the latter case at least the translation agency PAYS for the work done.

Otherwise somebody (who?) evaluates my work using some mysterious "quality criteria" that are NOT defined and comes to the conclusion, that I am not qualified - but, of course, cannot tell me why. I am sentenced quilty, but do not get a chance to defend myself (my work).

Typical example of a response from such a company:

"Our evaluators checked your translation strictly against the same criteria our Clients evaluate us, and we regret to inform you that your translation was not awarded a passing mark. We undertand the disappointment but in compliance with internal policies, evaluation details are kept confidential."

In those cases in which the other party had the courage to show me (again an experience that probably ALL translators worldwide share) their "corrections" (those little red marks all over the paper), they usually turn out to be insignificant stylistic changes or even outright mistakes. 


To quote someone from a (translators) mailing list:

"If you actually ask them to make a list of what is actually "wrong", most claims are usually unfounded (style issues, minor formatting, ambiguous source text, in-house company-specific abbreviations, job titles etc). 
Style issues are particularly bad for English where there often myriads of alternatives but you can only pick _one_ word. Customer A wants that word, but Customer B wants one of the other ones and Customer C wants something different again.
Quite often also, the "issues" disappear completely as soon as you ask the agency to put something in writing."


In what other industry and for what possible product/service would this kind of claim possible? For a reclamation about a defective product you have to produce evidence of the shortcoming/defect. If you take an examination, it is that you get back at least your grades. 

If a translator does a trial which is then rejected, the company that considers the quality of that trial inferior, must certainly be very confident about the quality of their own work and editors who evaluated the trial. If they are absolutely right and have so much confidence -> well then there cannot be any sensible reason for this secrecy! 

For these reasons I have to decided NOT to do any trials any more. Below I provide a number of actual translation samples. Check / investigate / judge them any which way you choose. If you like them: fine. If not: I am sorry.

Thomas Blasejewicz

***  the following selection of samples is still in the process of being assembled ***

Translation samples

Source Translation
English 

(Subject area: Diagnostic device)

1. Introduction

The devices are automated hematology analyzers for in vitro diagnostic use in clinical laboratories. The devices can analyze and output the results of 24 parameters of a blood sample. The devices perform analysis of WBC with an optical detector block based on the flow cytometry method, using a semiconductor laser. The RBCs and platelets are analyzed by the RBC detector using the Hydro Dynamic Focusing method.

Hemoglobin (HGB) is analyzed by the HGB detector based on the SLS hemoglobin detection method.

Analysis data is displayed on the IPU. The screens shown in these instructions are device XY-2134 screens.

On the XY-2135 screens, device XY-2135 is displayed for the instrument name at the top left of the screen, and for the Main Unit model name at the lower left.

  The devices are equipped with a rinse cup - after aspiration of a sample or control blood the probe is automatically cleaned. It is no longer necessary to wipe the sample probe.

We have been trying hard to keep the noise generation as low as possible. For non-operating periods the compressor can be switched off.

German / medical

1. Einleitung

Bei diesen Geräten handelt es sich um automatisierte, Hämatologieanalysatoren für die in vitro Diagnose in klinischen Labors. Die Geräte können 24 Parameter der Blutproben analysieren und die Ergebnisse ausgeben. Die Geräte analysieren das Blutbild mit einem auf dem Flusszytometrieverfahren basierenden optischen Detektorblock unter Einsatz eines Halbleiterlasers.

Das rote Blutbild und die Thrombozyten werden mit dem das hydrodynamische Fokusierverfahren einsetzenden RBZ-Detektor analysiert.

Hämoglobin (HGB) wird mit dem auf dem SLS Hämoglobin Nachweisverfahren basierenden HGB-Detektor analysiert.

  Die Analysedaten werden dann auf der IPU angezeigt. Bei den in diesen Anleitungen gezeigten Bildschirnanzeigen handelt es sich um die Bildschirmanzeigen des Modells XY-2134.

Auf dem Bildschirm des XY-2135 wird links oben XY-2135 als Instrumentenbezeichnung und links unten als Bezeichnung für das Hauptmodell angezeigt.

  Die Geräte sind mit einem Spülbecher ausgestatte t, der nach Aspiration einer Probe oder einer Blutkontrolle automatisch gerein igt wird. Es ist nicht mehr notwendig, die Sonde abzuwischen .

Wir haben uns sehr darum bemüht, die Geräuschen twicklung so gering wie möglich zu halten. Der Kompressor kann ausgeschaltet werden, wenn das Gerät nicht genutzt wird.

 

Japanese 課題4

 A型肝炎ウイルス感染がアトピー性疾患を予防するか?

過去50年間のアトピー性疾患発生数の劇的な増加から、環境要因が関与していることが示唆される。スタンフォード大学の研究チームが、A型肝炎ウイルス(HAV)の感染率低下が原因となっている可能性があるというエビデンスを発表している。

 

English / medical

Topic 4

Can a hepatitis A infection provide protection against atopic dermal diseases?

Over the past 50 years the incidence of atopic dermal diseases had dramatically increased, suggesting an involvement of environmental factors. A research team at Stanford University has published evidence that a reduction in the rate of infection with hepatitis A virus (HAV) may possibly be the cause.

 

     したがって、原田病はHLA-DR4以外にも発症に関与する要因が複数存在する多因子疾患であると考えられます。しかしながら、今までに原田病とHLA遺伝子以外の遺伝子の相関に関する報告はありません。そこで、本研究ではHLA-DR4以外の原田病の疾患感受性遺伝子を検索するため、まずHLAクラス関連遺伝子(MIC遺伝子、RAET1遺伝子、HFE遺伝子)が多く存在する第6染色体とサイトカインなど免疫に関係する遺伝子が多く存在する第1染色体について網羅的なマイクロサテライト解析を行いました。

     このD6S1581マイクロサテライトの周囲には約50kbテロメア側にMAS1遺伝子, 100kbテロメア側にIGF2R遺伝子, 60kbセントロメア側にはMRPL18遺伝子, 80kbセントロメア側にはACAT2遺伝子, そして約100kbセントロメア側にはWTAP遺伝子などが存在しています。これらの遺伝子は肝細胞癌、乳癌、類表皮癌、精神発達遅延、Wilms腫瘍と正の相関をすることが報告されています。しかし、原田病のような炎症性疾患や自己免疫性疾患との正、および負の相関は知られていません。

6染色体上にはHFE遺伝子やMIC遺伝子のほかにもRAET1L(retinoic acid early transcript 1L)遺伝子というHLAクラス1関連遺伝子が存在します。しかしながら、RAET1L遺伝子の最も近傍に位置するD6S1654マーカーでは、その多型と原田病に有意な相関は見られませんでした。このことから, RAET1L遺伝子が原田病の発症に関与している可能性は低いと考えられます.

 

(1)          Accordingly, Vogt-Koyanagi-Harada disease is considered to be a multifactorial disease in which besides HLA-DR4 multiple other factors are involved in its development. Yet, so far no reports have dealt with the correlation between other genes than the HLA gene and Vogt-Koyanagi-Harada disease. In the present study we began with the performance of a microsatellite analysis of HLA class I related genes (MIC gene, RAET1 gene, HFE gene) present on the sixth chromosome and many genes related to cytokines and immunity present on the first chromosome in order to search for Vogt-Koyanagi-Harada disease sensitive genes other than the HLA-DR4.  

(2)          In the vicinity of this D6S1581 microsatellite the MAS1 gene is located about 50 kb telomerically, the IGF2R gene about 100 kb telomerically, the MRPL18 gene about 60 kb centromerically, the ACAT2 gene about 80 kb centromerically and finally the WTAP gene about 100 kb centromerically. These genes have been reported to be positively correlated to hepatocellular carcinoma, breast cancer, epidermoid cancer, mental retardation and Wilms tumor. Yet, neither positive nor negative correlations with Vogt-Koyanagi-Harada disease or autoimmune diseases are known.  

(3)          On the sixth chromosome, the HLA class I related RAET1L (retinoic acid early transcript 1L) gene is also present apart from the HFE or the MIC genes. However, the D6S1654 marker located closest to the RAET1L gene does not show any significant correlation to this polymorphic Vogt-Koyanagi-Harada disease. Based on these findings an involvement of the RAET1L gene in the development of Vogt-Koyanagi-Harada disease seems to be unlikely.

 

Particularly advantageous results can be achieved by ensuring that the coatings according to this invention contain 15-50% polyvinylpyrrolidon/polyvinyl acetate mix polymerisate (ratio 6:4) and 15-45% hydroxypropyl ethylcellulose and where the sum of both substances should always be at least 65% and maximally 95% of the total weight of the coating composed of the three coating substances a), b) and c). The rest weight of 5% to 35% is in each case polyethylenglycol, that preferable should have a melting point of over 60ºC. However, a polyethylenglycol of lower melting point (for example 50ºC) – so-called polywax 6000, may also be employed. Percentages pertaining to the composition of these coatings should be understood in such a way that the sum of a), b) and c) is 100%. Eventually added dyes, pigments or flavoring agents are not included in this calculation.

白虎加人参湯は石膏Gypsum,粳米Rice,知母Common anemarrhena rhizone,甘草Licoriceの四味よりなる清熱生津の白虎湯に,補気生津の人参が配合された方剤である.中医学的な効能は清熱瀉火・生津止渇・補気で,熱盛による気津両傷(気津両虚)に適用する.すなわち,白虎湯に準じ,気分熱盛(陽明病経証)で脱水と気虚を伴う熱性疾患で,舌質は紅から鮮紅で乾燥あるいは沢・舌苔は少から無,脈は洪・大など力のあり,体液が欠乏して体力的に疲労が加わってきたときの症状で,多汗を呈し,口内は乾燥し口渇がひどく水を飲みたがり,体に火照りや灼熱感があったり,局部的な皮膚の熱感や痒みなどが現れたりするものに用いることが出来るとされる.

 著者はこれまでに,多形滲出紅斑をはじめとして掌蹠膿疱症(Palmoplantar pustulosis) や顔面の難治性紅斑(Erythema),蕁麻疹(Urticaria)などに対する白虎加人参湯加味の有効例を報告してきた.白虎加人参湯は多形滲出性紅斑以外にも中医学的に胃熱による津損と弁証された場合には用いてみる価値のある方剤であり,皮膚科領域において広く応用されるべきであると考える.

 
           Byakko Ka Ninjin To contains the four ingredients gypsum, rice, common anemarrhena rhizome and licorice. It therefore is characterized by the actions of its two constituents Byakko To clearing heat and promoting fluid production and Ninjin To induced qi tonification and increased fluid production. The Kampo medicinal effects of clearing heat and draining fire, promoting fluid production and alleviating dryness as well as supplementing qi are suitable for the treatment of injuries of both qi and fluid (qi and fluid deficiency). In other words, indications for Byakko To include the qi aspect of exuberant heat(channel pattern in yang brightness disease) of febrile diseases marked by dehydration and qi deficiency, the tongue being either crimson or bright red, lustrous with little or no fur, flooding, big and powerful pulse, while body fluids are deficient. When this combines with physical exhaustion it gives rise to symptoms including profuse sweating, oral dryness, in severe cases marked thirst, feeling of heat or burning, locally the skin can feel hot and may be itching.

           The author has used Byakko Ka Ninjin To in the past apart from the treatment of erythema exudativum multiforme also for palmoplantar pustulosis or refractory erythema of the face, urticaria and similar conditions and reported successfully treated cases. Byakko Ka Ninjin To can be used besides erythema exudativum multiforme also for patterns identified as fluid injury due to stomach-heat, indicating that it may have wide applications in dermatology.

 

Den "Antrag auf Altersauszahlung der Volks- und Arbeitnehmerrentenversicherung" (D/J1) betreffend Vielen Dank für das Verständnis, dass Sie den Aktivitäten der Sozialversicherung immer entgegen bringen.

Hinsichtlich des von Ihnen vorgelegten "Antrag auf Altersauszahlung der Volks- und ArbeitnehmerrentDenversicherung" (D/J1) haben wir jetzt an Hand der derzeit vorliegenden Eintragungen mit der Untersuchung zur Entscheidung über Ihre japanische Rente begonnen. Allerdings gibt es dabei noch Unklarheiten, derentwegen wir uns hiermit bei Ihnen erkundigen möchten.

Daher möchten wir Sie recht herzlich bitten,den Abschnitt "Beigefügte Unterlagen betreffend" von der zweiten Seite ab durchzulesen, die erforderlichen Unterlagen entweder zu besorgen oder auszustellen und dann dem zuständigen Sachbearbeiter zuzuschicken.Dieser schriftlichen Anfrage sind die folgenden Unterlagen beigefügt. 

*   Kopie des von Ihnen eingereichten D/J1.

*             Begründung warum der Arbeitnehemerversichertenschein nicht beigefügt werden kann.

*             Von Ihnen vorgelegte Anmeldung betreffs des vorgelegten Steuerabkommens (2 Ausfertigungen)

*             Die Versicherungsdauerin Japan betreffende Posten (den Ehepartner betreffend)

ヤマグチヒロイチロウ氏の勤務証明書

 ヤムグチヒロイチロウ氏は、2000121日から2003331日にかけて当初は客員医師として、200341日から20031231日までは医師助手として、ドレースデン大学病院心臓センター心臓外科病院に勤務しました。心臓外科病院は、心臓外科(6年)と心臓外科集中治療(2年)の教育権を所持しています。

 ドレースデン大学病院心臓センターは、心臓と心臓外科専門の総合分野をカバーする最高医療の病院です。先天性心臓弁膜症患者や心肺移植を予定する心臓疾患の末期患者も治療します。

 心臓外科病院は、ベッド総数80床、手術室4室、外科集中治療室(人工呼吸器付ベッド25床)、中間・標準看護病室を備えています。さらに心臓外科と移植術の外来患者の術前・術後の治療を行っています。

 ヤマグチ氏は、冠状血管、心臓周辺血管、縦隔、心臓弁膜の疾患、後天性心臓弁膜症等の診断、指示、手術治療に豊富な知識を備えています。

 

Arbeitsbescheinigung für Herrn Hiroichiro Yamaguchi

Herr Hiroichiro Yamaguchi war vom 1.Dezember 2000 bis zum 31.März 2003 anfänglich als Gastarzt und später vom 1. April 2003 bis zum 31. Dezember 2003 als Assistenzarzt in der Klinik für Herzchirurgie des Herzzentrums der Dresden Universitätsklinik angestellt. In der Klinik für Herzchirurgie hat er Anrecht auf Ausbildung in der Abteilung für Herzchirurgie (6 Jahre) und der herzchirurgischen Intensivstation (2 Jahre).

Die Klinik für Herzchirurgie des Herzzentrums der Dresden Universitätsklinik ist ein Krankenhaus für höchst entwickelte medizinische Versorgung auf allen Kardiologie und Herzchrirugie betreffenden Fachgebieten. Hier werden auch Patienten mit angeborenen Herzklappenfehlern und für Herz-Lungentransplantationen vorgesehene Patienten mit terminalen Herzkrankheiten behandelt.

Die Klinik für Herzchirurgie hat insgesamt 80 Betten, 4 Operationssäle, chirurgische Intensivstationen (25 Betten sind mit Respiratoren ausgestattet), sowie Zwischen- und Standardkrankenzimmer. Darüber hinaus werden auch ambulante Patienten vor herzchirurgischen Operationen oder Transplantationen behandelt sowie postoperative Behandlungen durchgeführt.

Herr Yamaguchi verfügt über ein ausgedehntes Wissen im Zusammenhang mit Diagnose, Behandlungsanweisungen und chirurgischer Behandlung von Koronargefäßen, perikardialen Gefäßen, Herzklappenkrankheiten und kongenitalen Klappenfehlern.

 

本実験において、顔面温度測定部位として、迎香(Yingxiang)、地倉(Dicang)

顴髎(Quanlian)、眼窩(Orbit point)を選択した。これらの部位を選択した理由は、迎香は、合谷(Hegu)と同じ経絡である手の陽明大腸系の終末にあたり、合谷での刺激が最も顕著に現れると考えたからである。一方、地倉は足の陽明胃系であり合谷とは異なる経絡の終末であるが、同じ陽明系に属すことから選択した。顴髎は、手の太陽小腸系の終末であり、迎香、地倉とは異なるが合谷と同じ手から始まる経絡であるため選択した。眼窩はツボ刺激による温度変化の影響を受けにくいと考え、コントロールとして選択した。

 

           In these experiments the points Yingxiang (LI20), Dicang (St4), Quanlian (SI18) and the Orbital Point were selected as locations for the measurement of facial temperature. The reason of the selection of these locations is that Yingxiang (LI20) is a terminal point on the "brighter yang (yang ming) large intestine of the hand " meridian on which Hegu (LI4) is also found. It is thus assumed that stimulation of Hegu will produce here the most pronounced effects. Conversely, Dicang was selected because it lies on the "brighter yang stomach of the leg" meridian and is thus a terminal point of a different channel than that of Hegu, but still belongs to the same brighter yang system. Yingxiang was selected because it is a terminal point of the "hand greater yang small intestine" meridian and again lies on a channel different from those of Yingxiang and Dicang, but still starts similar to Hegu on the hand. Stimulation of the orbital point is considered to have little effect on temperature variation and has thus been selected to serve as a control. 

 

[2] 

血糖降下治療としてインスリンまたは経口血糖降下薬を使用している糖尿病患者における骨折リスクをコホート内症例対照研究において検討した。 このコホートには糖尿病外来患者1,945人が含まれ、4.1年の追跡中に83人が骨折した。 症例と年齢、性、罹病期間などが一致する対照例249人との比較を行った。 過去10年間にメトホルミンおよびインスリンを36ヶ月以上使用していた場合のモデルを解析した結果、骨折とこれらの薬剤使用に有意な関連は認められなかった。 骨折時に血糖降下療法を開始していた別のモデルを解析したところ、男性ではインスリン療法と骨折に有意な関連がみられたが、女性では認められなかった。 メトホルミンでインスリン感受性を高める治療は骨折率を上昇させないことから、チアゾリジン系薬剤使用で報告されている骨代謝への悪影響はインスリン血症の軽減によるものではなく同薬剤の骨代謝への特異的な作用に起因する可能性が高いと考えられる。 インスリン増加を伴う治療を開始してから短期的には骨折のリスクが上昇するものの、使用が長期に及ぶと骨折への影響はみられなくなる。

 

[2] 

The fracture risk in diabetics using insulin or oral hypoglycemic agents as a hypoglycemic therapy was investigated in a cohort case-control study. 

This cohort included 1,945 ambulatory diabetics among whom fractures occurred in 83 persons during the follow-up period of 4.1 years. Patients were compared to a control group of 249 persons with matched age, sex and duration of morbidity. The results of an analysis of a model of Metformin or insulin administration for more than 36 months during the past 10 years did not reveal any significant correlation between the use of these drugs and fractures. Analysis of a different model in which hypoglycemic therapy was started at the time of the fracture revealed a significant correlation between the insulin treatment and fractures among men, but not in women. Based on the fact that treatment with Metformin to increase insulin sensitivity does not increase the incidence of fractures it appears to be highly likely, that the reported adverse influence on bone metabolism caused by the use of thiazolidine class drugs is not due to an improvement of the insulinemia, but rather to the specific effects of this drug on bone metabolism. Even if there may be an increased short-term risk of fractures from the start of a treatment associated with an increase in insulin, an influence on fractures is no longer observed during prolonged application.

 
    
   

 

Comments: